Literature DB >> 31590184

Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.

Brad Spellberg1, Travis B Nielsen2, David N Gilbert3, Andrew F Shorr4, Eric P Brass5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31590184      PMCID： PMC7296826          DOI： 10.7326/M19-1893

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  7 in total

1.  Medicine's responsibility in the propagation of poor protoplasm.

Authors:  A S JOHNSON
Journal:  N Engl J Med       Date:  1948-05-27       Impact factor: 91.245

2.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-08-13       Impact factor: 9.079

3.  New Societal Approaches to Empowering Antibiotic Stewardship.

Authors:  Brad Spellberg; Arjun Srinivasan; Henry F Chambers
Journal:  JAMA       Date:  2016 Mar 22-29       Impact factor: 56.272

4.  Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

Authors:  Travis B Nielsen; Eric P Brass; David N Gilbert; John G Bartlett; Brad Spellberg
Journal:  N Engl J Med       Date:  2019-06-19       Impact factor: 91.245

Review 5.  Adaptive platform trials: definition, design, conduct and reporting considerations.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2019-08-28       Impact factor: 84.694

6.  Round table: are new antibiotics needed?

Authors:  M Finland; W M Kirby; Y A Chabbert; E B Chain; H F Dowling; L P Garrod; C W Pettinga; A C Todd
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

7.  The future of antibiotics and resistance.

Authors:  Brad Spellberg; John G Bartlett; David N Gilbert
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245
  7 in total
  2 in total

1.  Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection.

Authors:  Travis B Nielsen; Jun Yan; Brian M Luna; Yuli Talyansky; Matthew Slarve; Robert A Bonomo; Brad Spellberg
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 7.759

2.  A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.

Authors:  Laura J V Piddock; Jean-Pierre Paccaud; Seamus O'Brien; Michelle Childs; Rohit Malpani; Manica Balasegaram
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.